Company intelligence / Profile preview

Cambrex

East Rutherford, New Jersey, USAcambrex.com ↗

Ownership: Public · CBM
Employees: ~2200
Development stage: Commercial

Overview

Cambrex provides end-to-end contract development, analytical, and manufacturing services for small molecule APIs and finished dosage forms. It has expanded capabilities to include analytical support for biological drugs but does not have its own clinical pipeline or results.

Modalities: Small moleculeBiologic (analytical and development services)Active pharmaceutical ingredient (API)Drug product manufacturing
Industry: Contract Manufacturing Organization

Financials

Market cap: $513.6M
Total revenue: $65.4M
Enterprise value: $635.2M

Beyond the preview

Go deeper on Cambrex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cambrex.